Chugai, Kowa, Sanofi deal

Chugai granted Kowa and Sanofi rights to co-develop Chugai's diabetes compound CSG452 in Japan. The three partners will co-develop the product, while Kowa and Sanofi will be responsible for submitting regulatory applications. Chugai, which will manufacture the product, is eligible for milestones. The sodium-glucose cotransporter 2 (SGLT2) inhibitor is in Phase III testing in Japan to treat Type II diabetes. Chugai, which declined to provide a timeline for Phase III data, said it expects submit regulatory applications next year. The company also said it is "conducting licensing activity" for the product outside Japan. ...